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data covering the period between January 2000 and December 2005. The outcome 
variables captured cost of readmissions for a CVD-related condition following an 
index CVD-related admission. The covariate of interest was an indicator variable for 
a discharge AMA in the index hospitalization. The difference in the cost of readmis-
sions (at 7-, 31-, 180-, and 365- day intervals) following formal discharges and dis-
charges AMA was examined using Heckman sample selection models and log linear 
models. The Heckman sample selection model was found to provide a better repre-
sentation of the data generation process. RESULTS: The sample included 443,049 
patients, of which 24,823 (5.6%) were readmitted to the same hospital. Approxi-
mately 1% of the patients who were readmitted to the hospital during the study period 
left AMA on the index admission while 0.87% of those who were not readmitted left 
AMA (p < 0.001). The cost of the ﬁrst readmission within 180 days was 9% (p = 
0.03) higher for patients discharged AMA on index admission compared to those who 
were discharged formally. The cost of all readmissions within 180 days and 365 days 
were 10% (p = 0.02) and 9% (p = 0.02) higher for patients discharged AMA on index 
admission compared to those who were discharged formally. CONCLUSIONS: A 
self-discharge AMA among patients admitted for CVD is associated with higher 
readmissions costs when readmissions occur within 6 months or 1 year.
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OBJECTIVES: To identify the differences in the number of restenosis after the place-
ment of sirolimus-eluting stent vs. zotarolimus-eluting stent and measure their related 
costs. METHODS: A literature review was conducted to identify meta-analysis or 
randomized clinical trials (RCT) that compared sirolimus-eluting (SES) and zotaroli-
mus-eluting (ZES) stents. The clinical outcome of interest was angiographic restenosis 
after stent placement given that this is a surrogate ending point that may predict late 
mortality. The results of the SORT OUT III trial with 2,333 patients were used which 
demonstrated that SES offered a lower rate of restenosis vs ZES (0.25% vs 1.25%) 
(HR: 4.62; 95 CI, 1.33–16.1, p = 0.02) (Lassen, 2008). The perspective is from a 
private payer in Brazil. Local guidelines for economic evaluation of health care tech-
nologies were followed (Vianna, 2007). A decision model was built in Excel. Resource 
usage was raised in a panel with hospitals and valued by micro-costing based on public 
sources (CBHPM 5th edition, PROAHSA, Brasíndice and SIMPRO). Only direct costs 
were considered and reported in 2010 Brazilian Reais (USD1 = R$1.75). Discount 
rate was not applied given the 1-year horizon of the study. A 500,000 cohort was 
taken for a revascularization incidence of 932/100,000 (Ryen, 2009). A one-way 
sensitivity analyses was performed. RESULTS: Based on our model SES patients had 
fewer cases of restenosis vs ZES (12 vs 58).Total cost for the SES group was 1.87% 
below the one found in the ZES group (R$ 29,008 vs R$ 29,559). CONCLUSIONS: 
Results suggest SES patients had a risk reduction of restenosis compared with ZES 
patients. Besides SES offer a 1.87% potential reduction in costs.
PCV68
COST-EFFECTIVENESS OF GENOTYPE-DRIVEN ANTIPLATELET 
THERAPY FOR SECONDARY PREVENTION AFTER ACUTE CORONARY 
SYNDROME
Crespin DJ1, Federspiel JJ2, Biddle AK1, Jonas D3, Stearns SC1, Rossi JS4
1Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel 
Hill, NC, USA, 2Gillings School of Global Public Health and School of Medicine, University of 
North Carolina at Chapel Hill, Chapel Hill, NC, USA, 3School of Medicine, University of 
North Carolina at Chapel Hill and Cecil G. Sheps Center for Health Services Research, 
Chapel Hill, NC, USA, 4School of Medicine, University of North Carolina at Chapel Hill, 
Chapel Hill, NC, USA
OBJECTIVES: Clopidogrel’s effectiveness is reduced signiﬁcantly for secondary pre-
vention of thrombotic events after acute coronary syndrome (ACS) in patients with 
CYP2C19*2 mutations. Ticagrelor, a novel antiplatelet agent, does not require activa-
tion by the CYP2C19 enzyme and was superior to clopidogrel in a recent secondary 
prevention trial. In 2011, clopidogrel will lose its patent protection and likely will be 
substantially less expensive than ticagrelor. We aim to determine the cost-effectiveness 
of genotype-driven treatment, in which ticagrelor is prescribed in the presence of 
CYP2C19*2 mutations and clopidogrel in their absence, compared to prescribing 
ticagrelor universally. METHODS: A hybrid decision tree/Markov model was used to 
derive 30-year medical costs (in 2009 US$) and outcomes for a cohort of Medicare 
ACS patients of age 65 receiving either a genotype-driven or ticagrelor-only treatment. 
Outcomes included life years and quality-adjusted life years (QALYs) gained. Data 
comparing the clinical performance of ticagrelor and clopidogrel were derived from 
the PLATO study. Mortality and repeat myocardial infarction risk were estimated 
using Medicare inpatient claims of ACS patients. Costs and quality adjustments were 
derived from literature reviews. RESULTS: Over a 30-year period the incremental 
cost-effectiveness ratio (ICER) for universal ticagrelor was $8,827 per QALY com-
pared to genotype-driven treatment. Universal ticagrelor and genotype-driven treat-
ment had respective per capita costs of $10,096 and $8,868. Universal ticagrelor 
resulted in 0.14 QALYs gained per person relative to genotype-driven treatment. The 
ICER was most sensitive to the price of ticagrelor and the hazard ratio for death for 
ticagrelor compared with clopidogrel and remained below $50,000 per QALY until 
a monthly price of $737 for ticagrelor or a 0.93 hazard ratio for death for ticagrelor 
relative to clopidogrel. In probabilistic analyses, the ICER was below $50,000 per 
QALY in 97.4% of simulations. CONCLUSIONS: Prescribing ticagrelor universally 
increases quality-adjusted life expectancy for ACS patients at a cost below typically 
accepted thresholds.
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OBJECTIVES: To assess the cost-effectiveness of rosuvastatin 20 mg for prevention of 
major cardiovascular disease (CVD) events and mortality compared with no treatment 
alternative in a higher CVD risk population based on ﬁndings from JUPITER (Justiﬁca-
tion for the Use of statins in Primary prevention: an Intervention Trial Evaluating 
Rosuvastatin). METHODS: A probabilistic Monte Carlo simulation model estimated 
long-term cost-effectiveness of rosuvastatin therapy (20 mg daily) for the prevention of 
CVD mortality and morbidity. Using outcomes data from the JUPITER trial, the rela-
tive risk reduction of rosuvastatin 20 mg compared with no treatment was carried 
forward beyond the trial period. Baseline CVD event risk was age adjusted using 
Framingham equation. Cost- effectiveness was assessed from a payer perspective using 
direct medical costs and a lifetime horizon. Life tables and CVD-attributable mortality 
risk estimates were derived from Mexican national statistics data. Results are presented 
in U.S. dollars (exchange rate 13 MXN/dollar). RESULTS: The model was run for a 
hypothetical cohort of 100,000 patients at higher risk of CVD events (men 61%, age 
67 years, mean Framingham risk 15%). Estimated quality adjusted life years (QALYs) 
gained with rosuvastatin therapy compared with no treatment was 31,723 over lifetime 
and 23,946 over a 20-year horizon. Over lifetime, 11,680 events were avoided: 6,076 
non-fatal MIs, 2,596 non-fatal strokes, and 3,729 CVD deaths. The estimated incre-
mental cost-effectiveness ratio (ICER) for cost per QALY was $8,91 for a lifetime 
horizon. For a hypothetical cohort similar to the overall JUPITER population, the ICER 
was $11,764/QALY over lifetime. For a 20-year horizon, similar ICERs were estimated 
for the higher-risk ($11,327/QALY) and JUPITER patient populations ($16,279/
QALY). CONCLUSIONS: In a higher-risk Mexican population with the mean Fram-
ingham risk of 15%, treatment with rosuvastatin 20 mg daily is a cost-effective treat-
ment alternative if the willingness to pay per QALY is higher than $8291.
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OBJECTIVES: To assess cost-effectiveness of rosuvastatin 20 mg treatment in second-
ary prevention of major cardiovascular disease (CVD) events and mortality for 
patients with a previous CVD event. METHODS: A probabilistic Monte Carlo simula-
tion model estimated long-term cost-effectiveness of rosuvastatin therapy (20 mg 
daily) for prevention of CVD mortality and morbidity in patients with a previous CVD 
event (60% men, age 61 years, mean Framingham score 25%). The relative risk 
reduction observed with rosuvastatin 20 mg in the JUPITER (Justiﬁcation for the Use 
of statins in Primary prevention: an Intervention Trial Evaluating Rosuvastatin) trial 
was used in this secondary-prevention setting based on available literature indicating 
similar efﬁcacy of statins in primary- and secondary-prevention settings. The quarterly 
event probabilities were used to construct survival curves for patients in both the 
treatment and placebo groups. The relative risk of rosuvastatin was estimated and 
extrapolated beyond the trial duration. The event rates were age adjusted beyond the 
trial duration. The difference in baseline risk between the JUPITER trial population 
and population of interest was adjusted using Framingham score. A payer perspective 
was assessed with direct medical costs and up to a lifetime horizon. RESULTS: For a 
hypothetical cohort of 100,000 patients with a previous history of CVD and 25% 
Framingham risk score, estimated quality-adjusted life-years (QALYS) gained with 
rosuvastatin therapy compared with placebo was 54,319 over lifetime, and 39,252 
and 15,341 over 20-year and 10-year horizons, respectively. Rosuvastatin 20 mg 
avoided 14,373 events over lifetime (8,327 non-fatal MIs, 3,218 non-fatal strokes, 
and 4,292 CVD deaths avoided). Rosuvastatin 20 mg dominated (more effective and 
less costly) over lifetime and 20-year time horizon. The incremental cost-effectiveness 
ratio for cost per QALY over 10 years was $18,549. CONCLUSIONS: Results indi-
cate rosuvastatin 20 mg to be cost-effective in secondary-prevention treatment of 
patients with a history of CVD events.
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OBJECTIVES: To evaluate the costs, beneﬁts, and incremental cost-effectiveness of 
non-invasive imaging of cardiac sympathetic innervation using AdreView in patients 
